Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
3,882
Views
21
CrossRef citations to date
0
Altmetric
Original Research

VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma

Hai-Xia Hea State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Yan Gaoa State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Jian-Chang Fua State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;c Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Qiang-Hua Zhoud Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;e Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, ChinaView further author information
,
Xiao-Xiao Wanga State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Bing Baia State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Peng-Fei Lia State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Cheng Huanga State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Qi-Xiang Ronga State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Li-Qin Pinga State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Yan-Xia Hea State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Jia-Ying Maoa State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaView further author information
,
Xu Chend Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;e Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, ChinaCorrespondence[email protected]
View further author information
&
Hui-Qiang Huanga State Key Laboratory of Oncology in South China & Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China;b Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 1907059 | Received 02 Feb 2021, Accepted 17 Mar 2021, Published online: 07 Apr 2021

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Orhun Akdoğan, Osman Sütcüoğlu, Betül Öğüt, Nalan Akyürek, Nuriye Özdemir, Ahmet Özet & Ozan Yazıcı. (2022) Effect of Neoadjuvant Therapy on Tumor Tissue PD-L1 and VISTA Expression Levels in Non-Small-Cell Lung Cancer. Immunotherapy 14:14, pages 1121-1131.
Read now
Zhengyu Wei, Yiming Shen, Chongchang Zhou, Yujie Cao, Hongxia Deng & Zhisen Shen. (2022) CD3D: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma. Bioengineered 13:5, pages 13784-13800.
Read now

Articles from other publishers (19)

Aida Jlassi, Rim Rejaibi, Maroua Manai, Ghada Sahraoui, Fatma Zahra Guerfali, Lamia Charfi, Amel Mezlini, Mohamed Manai, Karima Mrad & Raoudha Doghri. (2024) VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma. Frontiers in Oncology 14.
Crossref
Negar Hosseinkhani, Nima Hemmat, Elham Baghbani, Amir Baghbanzadeh, Tohid Kazemi, Ahad Mokhtarzadeh, Mahdi Jafarlou, Mohammad Amin Doustvandi & Behzad Baradaran. (2024) Dual silencing of tumor-intrinsic VISTA and CTLA-4 stimulates T-cell mediated immune responses and inhibits MCF7 breast cancer development. Gene 896, pages 148043.
Crossref
Fereshteh Rezagholizadeh, Fatemeh Tajik, Morteza Talebi, Seyed Reza Taha, Mahdieh Shariat Zadeh, Pooya Farhangnia, Hamideh Sadat Hosseini, Aram Nazari, Shabnam Mollazadeh Ghomi, Seyede Mahtab Kamrani Mousavi, Niloofar Haeri Moghaddam, Hossein Khorramdelazad, Mohammad Taghi Joghataei & Elahe Safari. (2024) Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma. Frontiers in Immunology 15.
Crossref
Bo Wang, Ziwei Ou, Wenlong Zhong, Lin Huang, Wenjian Liao, Yiyu Sheng, Zhixing Guo, Junyu Chen, Wenjuan Yang, Ke Chen, Xiaodong Huang, Tenghao Yang, Tianxin Lin & Jian Huang. (2023) Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant. Cancer Immunology Research 11:12, pages 1656-1670.
Crossref
Dia Roy, Cassandra Gilmour, Sachin Patnaik & Li Lily Wang. (2023) Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors. Frontiers in Immunology 14.
Crossref
Shengwei Mo, Long Zou, Ya Hu, Xiaoyan Chang & Jie Chen. (2023) Expression of PD-L1 and VISTA in Intraductal Papillary Mucinous Neoplasm With Associated Invasive Carcinoma of the Pancreas. Modern Pathology 36:9, pages 100223.
Crossref
Shumin Xu, Chenyang Wang, Lingge Yang, Jiaji Wu, Mengshu Li, Peng Xiao, Zhiyong Xu, Yun Xu & Kai Wang. (2023) Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy. Frontiers in Immunology 14.
Crossref
Yanxia He, Yan Gao, Liqin Ping, Haixia He, Cheng Huang, Bing Bai, Xiaoxiao Wang, Zhiming Li, Qingqing Cai, Yuhua Huang, Xueyi Pan, Wenbin Zeng, Yanan Liu & Huiqiang Huang. (2022) The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. Journal of Cancer Research and Clinical Oncology 149:5, pages 2017-2027.
Crossref
Shannon A. Carty, Carlos A. Murga-Zamalloa & Ryan A. Wilcox. (2023) SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Daniel Ren Yi Yap, Jing Quan Lim, Dachuan Huang, Choon Kiat Ong & Jason Yongsheng Chan. (2023) Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma. Frontiers in Immunology 14.
Crossref
Xi-Yang Tang, Yan-Lu Xiong, Xian-Gui Shi, Ya-Bo Zhao, An-Ping Shi, Kai-Fu Zheng, Yu-Jian Liu, Tao Jiang, Nan Ma & Jin-Bo Zhao. (2022) IGSF11 and VISTA: a pair of promising immune checkpoints in tumor immunotherapy. Biomarker Research 10:1.
Crossref
Shuxin Huang, Yujie Zhao, Pengjun Liao, Jinghua Wang, Zhiyan Li, Jiaxiong Tan, Xianfeng Zha, Shaohua Chen, Yangqiu Li & Liye Zhong. (2022) Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma. Frontiers in Oncology 12.
Crossref
Tongguo Shi, Shuru Zhou, Ting Zhang, Shiyang Han, Li Zhang, Fengqing Fu, Ruhong Yan & Xueguang Zhang. (2022) Establishment of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay to Measure Soluble B7-H5 in Patients with Cancer. Journal of Immunology Research 2022, pages 1-8.
Crossref
Nyanbol Kuol, Xu Yan, Vanessa Barriga, Jimsheena Karakkat, Stamatis Vassilaros, Ioannis Fyssas, Anastasios Tsimpanis, Sarah Fraser, Kulmira Nurgali & Vasso Apostolopoulos. (2022) Pilot Study: Immune Checkpoints Polymorphisms in Greek Primary Breast Cancer Patients. Biomedicines 10:8, pages 1827.
Crossref
Liju Zong, Yu Gu, Yuncan Zhou, Yujia Kong, Shengwei Mo, Shuangni Yu, Yang Xiang & Jie Chen. (2022) Expression of B7 family checkpoint proteins in cervical cancer. Modern Pathology 35:6, pages 786-793.
Crossref
Ming Huang, Wen Dong, Ruihui Xie, Jilin Wu, Qiao Su, Wuguo Li, Kai Yao, Yuelong Chen, Qianghua Zhou, Qiang Zhang, Wenwen Li, Liang Cheng, Shengmeng Peng, Siting Chen, Jian Huang, Xu Chen & Tianxin Lin. (2022) HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program. Cancer Communications 42:5, pages 447-470.
Crossref
Markus Albertsmeier, Annelore Altendorf-Hofmann, Lars H. Lindner, Rolf D. Issels, Eric Kampmann, Hans-Roland Dürr, Martin K. Angele, Frederick Klauschen, Jens Werner, Achim A. Jungbluth & Thomas Knösel. (2022) VISTA in Soft Tissue Sarcomas: A Perspective for Immunotherapy?. Cancers 14:4, pages 1006.
Crossref
Andreea Cătălina Tinca, Iuliu Gabriel Cocuz, Mihaela Cornelia Șincu, Raluca Niculescu, Adrian Horațiu Sabău, Diana Maria Chiorean, Andreea Raluca Szőke & Ovidiu Simion Cotoi. (2022) VISTA, PDL-L1, and BRAF—A Review of New and Old Markers in the Prognosis of Melanoma. Medicina 58:1, pages 74.
Crossref
Chenyang Wu, Xin Cao & Xiaojin Zhang. (2021) VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses. RSC Medicinal Chemistry 12:10, pages 1672-1679.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.